Following the publication of a research note on Emergent BioSolutions by StockNews.com on Thursday, it was announced that the website would begin providing coverage for the company’s shares.
The brokerage firm assigned a “sell” rating to the biopharmaceutical company’s shares.
On Monday, February 27, the public received Emergent BioSolutions’ (NYSE: EBS) quarterly earnings report.
The report was distributed to them electronically.
The earnings for the quarter of the biopharmaceutical company came in at $0.31, which was lower than the consensus estimate of $0.62 ($0.62) among industry analysts. For Emergent BioSolutions, the net margin and the return on equity were negative, at 19.97% and 7.57%, respectively.
The company’s most recent quarter’s revenue came in at $330.70 million, a significant increase over the consensus projection of $298.23 million.
The corporation achieved a profit of $4.50 per share during the same quarter of the previous year.
The quarterly revenue of Emergent BioSolutions experienced a decrease of 54.3% compared to the same period in the previous year.
The general opinion held by those who follow the market is that Emergent BioSolutions will report a loss of -0.07 cents per share for the current financial year.
When trading started on Thursday, the price of one share of Emergent BioSolutions common stock was $9.65.
This price remained unchanged throughout the trading day.
The simple moving average for the last 50 days of the company’s stock price is $12.98, and the simple moving average for the last 200 days is $15.71.
The company’s stock has a price-to-earnings ratio of -2.15, a beta value of 0.94, and a market capitalization of $483.85 million.
Emergent BioSolutions has seen its share price go as low as $9.17 over the past year, while it has reached a high of $45.14 during the same period.
The debt-to-equity ratio stands at 0.32, the quick ratio at 0.70, and the current ratio at 0.98.
In a separate piece of news, TheStreet lowered their rating of Emergent BioSolutions from “c-” to “d” on Monday, February 27.
A total of eight different recommendations have been made regarding the stock by research analysts.
These recommendations include four holds, one buy rating, one sell recommendation, and five hold ratings.
According to Bloomberg, the stock is currently rated “Hold” on average, and the general price goal for the stock is set at $36.75; this information was obtained from the company’s most recent earnings report.
Several hedge funds have adjusted how they invest their money in EBS over the past few months.
During the first three months of 2018, BlackRock INC increased the amount of Emergent BioSolutions stock owned by 8.1%, bringing its total ownership percentage to 100%.
BlackRock INC now has 8,731,904 shares in the biopharmaceutical business after purchasing an additional 655,003 shares during the most recent quarter to bring their total number to 8.
The value of these shares on the market currently is $358,533,000.
During the third quarter, Vanguard Group INC raised the amount of directly owned Emergent BioSolutions stock to a percentage that was 2.0% higher than before.
The most recent purchase of 101,059 additional shares brought the total number of Vanguard Group INC’s holdings in the biopharmaceutical company up to 5,191,486.
The value of these shares on the market currently is $108,969,000.
During the third quarter, State Street Corporation brought the total amount of Emergent BioSolutions stock that it owned to a level that was 4.0 percentage points higher. State Street Corp. now has a total ownership stake of 4,316,310 shares and a market valuation of $90,599,000 after purchasing an additional 165,678 shares during the most recent quarter.
This brings the total number of shares owned by State Street Corp.
To 4,316,310.
Dimensional Fund Advisors LP saw a rise of 33.4% in the size of its holdings in Emergent BioSolutions during the first three months of 2018.
Dimensional Fund Advisors LP now has 1,368,661 shares of the biopharmaceutical company thanks to the acquisition of 342,964 additional shares during the most recent reporting period.
These shares have a market value of $56,199,000.
During the last three months of 2018, Man Group plc increased the amount of Emergent BioSolutions stock owned by 34.3%.
Man Group plc now has 879,448 shares of the company’s stock after purchasing an additional 224,729 shares during the most recent quarter.
As a result, the company’s market capitalization has increased to $10,386,000.
The combined holdings of institutional investors and hedge funds account for 80.44 percent of the total number of shares in the company.
Emergent BioSolutions INC is in the business of creating new medical countermeasures, manufacturing those countermeasures, and selling them in retail outlets.
It provides goods intended to address hazards to the health of civilian and military populations that are either unintentional, malevolent, or naturally occur.
These hazards can be caused by natural disasters or by intentional acts.
This company offers a variety of products, some of which include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.